Type 2 diabetes management knowledge is always evolving. Here, we will examine how some diabetes management myths hold up ...

CompanyOverview|NYSE:NVO] Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

Patients who use GLP1 drugs to help control their type 2 diabetes are at an upward risk of developing age-related macular ...

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

The European Medicines Agency warns that Novo Nordisk's Ozempic and Wegovy may, in rare cases, cause NAION—a serious eye condition that can lead to vision loss. The EMA has asked the company to update ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

GLP-1s are gaining interest for their impact on weight, blood sugar, and possibly mood in bipolar disorder. Here’s what ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Omada Health shares climbed after the company made its debut on Nasdaq. The virtual healthcare company started trading shares at $19 on Friday morning, and they jumped 35% to $25.58 by midday. It ...

A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.